Analytical Data
-
Gene name
LILRA3
- Application
-
Alternative Names
LILRA3；ILT6；LIR4；Leukocyte immunoglobulin-like receptor subfamily A member 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8N6C8
-
Expression Region
19-439aa
-
AA Sequence
THVQAGPLPKPTLWAEPGSVITQGSPVTLRCQGSLETQEYHLYREKKTAL WITRIPQELVKKGQFPILSITWEHAGRYCCIYGSHTVGLSESSDPLELVV TGAYSKPTLSALPSPVVTSGGNVTIQCDSQVAFDGFILCKEGEDEHPQCL NSHSHARGSSRAIFSVGPVSPSRRWSYRCYGYDSRAPYVWSLPSDLLGLL VPGVSKKPSLSVQPGPVVAPGEKLTFQCGSDAGYDRFVLYKEWGRDFLQR PGRQPQAGLSQANFTLGPVSRSYGGQYTCSGAYNLSSEWSAPSDPLDILI TGQIRARPFLSVRPGPTVASGENVTLLCQSQGGMHTFLLTKEGAADSPLR LKSKRQSHKYQAEFPMSPVTSAHAGTYRCYGSLSSNPYLLTHPSDPLELV VSGAAETLSPPQNKSDSKAGEVDHHHHHH
-
Molecular Weight
47 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRA3 (Leukocyte Immunoglobulin Like Receptor A3) is a member of the leukocyte immunoglobulin-like receptor (LILR) family, known for its role in modulating immune responses. This receptor is predominantly expressed on immune cells such as monocytes, dendritic cells, and macrophages. LILRA3 has garnered attention due to its unique ability to inhibit pro-inflammatory activities, making it a crucial player in maintaining immune homeostasis and preventing excessive inflammation. Research indicates that dysregulation of LILRA3 is associated with various autoimmune diseases and inflammatory conditions, prompting investigations into its therapeutic potential. Recombinant LILRA3 proteins are being developed to study their functional roles and interactions with other immune components, as well as to explore their use as biomarkers for disease progression. Understanding LILRA3's signaling pathways and mechanisms of action could provide insights into novel immunotherapies, highlighting its significance in both immunology and potential clinical applications. This research aims to illuminate the intricacies of immune regulation and pave the way for innovative approaches in treating immune-related disorders, positioning LILRA3 as a focal point in contemporary immunological studies.
